Subtype of SCLC Is an Intrinsic and Persistent Feature Through Systemic Treatment

Introduction: SCLC is an aggressive malignancy with poor outcome. Most patients have disease recurrence despite treatments with multiple modalities. Subtyping of SCLC has been proposed recently, and novel agents targeting specific subtypes are actively being investigated. In this study, we evaluated...

Full description

Bibliographic Details
Main Authors: Ying-Chun Lo, MD, PhD, Joel Rivera-Concepcion, MD, George Vasmatzis, PhD, Marie-Christine Aubry, MD, Konstantinos Leventakos, MD, PhD
Format: Article
Language:English
Published: Elsevier 2023-09-01
Series:JTO Clinical and Research Reports
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S2666364323001042